{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:10:27Z","timestamp":1792188627636,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Medical Research Council"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jcin.2014.09.014","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T16:18:13Z","timestamp":1424189893000},"page":"292-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic Left Ventricular Dysfunction and Stunning Without a Detected Difference in Myocardial Substrate Utilization"],"prefix":"10.1016","volume":"8","author":[{"given":"Liam M.","family":"McCormick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Hoole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Axell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie J.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick E.J.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Dutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2014.09.014_bib1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jcin.2014.09.014_bib2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcin.2014.09.014_bib3","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2014.09.014_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jcin.2014.09.014_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10557-005-6892-4","article-title":"Glucagon like peptide-1 is protective against myocardial ischemia\/reperfusion injury when given\u00a0either as a preconditioning mimetic or at reperfusion in an isolated rat heart model","volume":"19","author":"Bose","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jcin.2014.09.014_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10557-007-6030-6","article-title":"Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in\u00a0vitro rat heart and may involve the p70s6K pathway","volume":"21","author":"Bose","year":"2007","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jcin.2014.09.014_bib7","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2014.09.014_bib8","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","article-title":"Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction","volume":"33","author":"Lonborg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2014.09.014_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCINTERVENTIONS.110.960476","article-title":"A\u00a0pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans","volume":"4","author":"Read","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2014.09.014_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCIMAGING.109.899377","article-title":"DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease","volume":"3","author":"Read","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcin.2014.09.014_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/hrt.2010.219345","article-title":"Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease","volume":"98","author":"Read","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jcin.2014.09.014_bib12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/CIRCIMAGING.113.000785","article-title":"Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease","volume":"7","author":"McCormick","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jcin.2014.09.014_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jcin.2009.12.014","article-title":"Stunning\u00a0and cumulative left ventricular dysfunction occurs late after coronary balloon occlusion in humans: insights from simultaneous coronary and left ventricular hemodynamic assessment","volume":"3","author":"Hoole","year":"2010","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2014.09.014_bib14","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2014.09.014_bib15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1161\/01.CIR.70.5.812","article-title":"Continuous measurement of left ventricular volume in animals and humans by conductance catheter","volume":"70","author":"Baan","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2014.09.014_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/bmj.3.5725.735","article-title":"Effect of heparin on serum free-fatty-acids, plasma catecholamines, and the incidence of arrhythmias following acute myocardial infarction","volume":"3","author":"Nelson","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.jcin.2014.09.014_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/cvr\/cvs123","article-title":"GLP-1 and cardioprotection: from bench to bedside","volume":"94","author":"Ravassa","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jcin.2014.09.014_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1475-2840-13-12","article-title":"Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1","volume":"13","author":"Clarke","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jcin.2014.09.014_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0008-6363(96)00245-3","article-title":"Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions","volume":"33","author":"Stanley","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jcin.2014.09.014_bib20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","article-title":"Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy","volume":"110","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2014.09.014_bib21","doi-asserted-by":"crossref","first-page":"e23570","DOI":"10.1371\/journal.pone.0023570","article-title":"Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia\/reperfusion injury: evidence for improving cardiac metabolic efficiency","volume":"6","author":"Bao","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jcin.2014.09.014_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0196-9781(03)00108-6","article-title":"Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium","volume":"24","author":"Kavianipour","year":"2003","journal-title":"Peptides"},{"key":"10.1016\/j.jcin.2014.09.014_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00395-013-0365-x","article-title":"Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus","volume":"108","author":"Moberly","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jcin.2014.09.014_bib24","doi-asserted-by":"crossref","first-page":"e83758","DOI":"10.1371\/journal.pone.0083758","article-title":"Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia","volume":"9","author":"Gejl","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcin.2014.09.014_bib25","doi-asserted-by":"crossref","first-page":"E1165","DOI":"10.1210\/jc.2011-3456","article-title":"Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes","volume":"97","author":"Gejl","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jcin.2014.09.014_bib26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cardfail.2012.07.009","article-title":"Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy","volume":"18","author":"Witteles","year":"2012","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jcin.2014.09.014_bib27","first-page":"H91","article-title":"Acute myocardial ischemia causes a transmural gradient in glucose extraction but not glucose uptake","volume":"262","author":"Stanley","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jcin.2014.09.014_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cvr\/25.2.158","article-title":"Changes in myocardial energy metabolism in elective coronary\u00a0angioplasty","volume":"25","author":"Peuhkurinen","year":"1991","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jcin.2014.09.014_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1475-2840-12-154","article-title":"Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner","volume":"12","author":"Hausenloy","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jcin.2014.09.014_bib30","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1161\/01.CIR.85.6.2247","article-title":"Preconditioning does not attenuate myocardial stunning","volume":"85","author":"Ovize","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2014.09.014_bib31","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0022-2828(95)90590-1","article-title":"Ischaemic preconditioning in a model of global ischaemia: infarct size limitation, but no reduction of stunning","volume":"27","author":"Jenkins","year":"1995","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jcin.2014.09.014_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/eurjhf\/hfp040","article-title":"Remote\u00a0ischaemic pre-conditioning does not attenuate ischaemic left ventricular dysfunction in humans","volume":"11","author":"Hoole","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jcin.2014.09.014_bib33","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/01.CIR.99.4.578","article-title":"Glucose for the heart","volume":"99","author":"Depre","year":"1999","journal-title":"Circulation"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879814016549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879814016549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:01:37Z","timestamp":1761847297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879814016549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S1936879814016549"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2014.09.014","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic Left Ventricular Dysfunction and Stunning Without a Detected Difference in Myocardial Substrate Utilization","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2014.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}